CITANEST Drug Patent Profile
✉ Email this page to a colleague
When do Citanest patents expire, and when can generic versions of Citanest launch?
Citanest is a drug marketed by Astrazeneca and Dentsply Pharm and is included in three NDAs.
The generic ingredient in CITANEST is epinephrine bitartrate; prilocaine hydrochloride. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the epinephrine bitartrate; prilocaine hydrochloride profile page.
Summary for CITANEST
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 98 |
Clinical Trials: | 2 |
Patent Applications: | 3,699 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CITANEST at DailyMed |
Recent Clinical Trials for CITANEST
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bozyaka Training and Research Hospital | Phase 4 |
Diskapi Teaching and Research Hospital | Phase 4 |